Celltrion Pharm, Inc.

068760.KQ

068760.KQCelltrion Pharm, Inc. KR flag

KOSDAQ

47,600.00

KRW

+50.00

(+0.11%)

2.07TMarket Cap

May 14Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7068760008

Return %

Stock

S&P500

-44.47

6.57

-36.74

22.75

-21.34

93.55

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	2,503.11	2,493.16	3,269.27	2,612.26	2,886.05	3,135.13	3,381.18	3,997.01	5,476.62	9,164.29	8,875.14	8,932.7	- -	11,017.83
Basic EPS, GAAP	189.3	123.72	287.5	-531.56	-581.17	62.65	-216.13	198.16	490.99	794.73	596.83	488.57	- -	506.49
Free Cash Flow per Basic Share	-4,021.26	-4,478.74	-868.21	-1,904.74	-851.3	-139.09	147.97	-96.77	-187.78	1,853.59	-237.53	42.7	- -	1,166.84
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	1,163.48	1,163.43	1,601.18	-139.3	-550.86	-97.83	-648.47	648.06	1,159.97	1,932.01	2,530.08	3,017.36	- -	3,534.91
Tangible Book Value per Share	6,143.97	5,784.23	7,724.58	5,365.56	6,503.85	5,854.81	5,391.61	5,613.12	6,155.22	6,723.49	7,252.56	7,751.29	- -	8,248.47
Basic Weighted Avg Shares	19	21	20	29	36	43	43	43	43	44	43	44	- -	43
Sales/Revenue/Turnover	46,968	52,657	66,744	74,732	104,811	135,860	146,880	173,513	233,568	398,738	386,040	388,794	477,835	477,835
Operating Margin (%)	10.81	14.23	12.51	-18.1	-14.32	6.38	2.43	8.49	10.12	11.99	9.89	9.28	7.79	7.79
Depreciation Expense	1,160	1,050	1,187	4,442	12,069	12,234	12,712	13,023	13,470	16,378	17,419	19,725	20,093	20,093
Net Income, GAAP	3,552	2,613	5,869	-15,207	-21,106	2,715	-9,389	8,602	20,940	34,579	25,960	21,265	21,966	21,966
Effective Tax Rate (%)	- -	27.86	0.68	- -	- -	- -	- -	2.74	- -	18.68	14.8	18.86	26.19	26.19
Profit Margin (%)	7.56	4.96	8.79	-20.35	-20.14	2	-6.39	4.96	8.97	8.67	6.72	5.47	4.6	4.6
Working Capital	34,237	114,273	34,864	36,860	99,455	86,816	54,926	39,717	46,027	71,226	99,920	115,485	144,023	144,023
LT Debt	64,065	165,570	84,401	114,089	89,000	48,125	34,375	38,811	57,851	39,398	21,823	5,862	15,089	15,089
Total Equity	157,246	168,412	214,426	192,314	276,706	293,624	270,035	280,031	300,561	331,969	356,787	376,666	396,922	396,922
Return on Invested Capital (%)	- -	1.82	2.27	- -	- -	- -	- -	3.35	- -	7.72	6.28	5.51	4.93	4.93
Return on Capital (%)	- -	2.29	4.34	- -	- -	- -	- -	8.87	- -	15.34	11.67	9.92	8.88	8.88
Return on Common Equity (%)	18.13	11.26	20.5	- -	- -	- -	- -	- -	53.97	51.79	26.75	17.62	15.43	15.43

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	23.38%	25.15%	22.9%
Net Income, GAAP	-90.18%	33.77%	3.3%
Free Cash Flow	108.75%	275.16%	2,623.03%
Total Cash Common Dividend	- -	- -	- -
Total Equity	7.16%	7.24%	5.38%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Jung-su Seo
Full Time Employees: 888
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 82, 2sandan-ro Cheongju South Korea
IPO Date: Feb 3, 2006
Website: celltrionph.com
Similar Companies: C21 Investments Inc. (CXXIF)
Gold River Productions, Inc. (GRPS)
NeutriSci International Inc. (NRXCF)
Esperion Therapeutics, Inc. (ESPR)
Canntab Therapeutics Limited (CTABF)
Juva Life Inc. (JUVAF)
Business: Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea.

	Jun'24	Sep'24	Dec'24
ST Debt	165,476	161,330	157,082
LT Borrowings	- -	- -	- -
LT Finance Leases	770	15,642	15,089
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	43	43	43
Market Capitalization	3,725,648	2,837,590	2,459,038

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	2,503.11	2,493.16	3,269.27	2,612.26	2,886.05	3,135.13	3,381.18	3,997.01	5,476.62	9,164.29	8,875.14	8,932.7	- -	11,017.83
Basic EPS, GAAP	189.3	123.72	287.5	-531.56	-581.17	62.65	-216.13	198.16	490.99	794.73	596.83	488.57	- -	506.49
Free Cash Flow per Basic Share	-4,021.26	-4,478.74	-868.21	-1,904.74	-851.3	-139.09	147.97	-96.77	-187.78	1,853.59	-237.53	42.7	- -	1,166.84
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	1,163.48	1,163.43	1,601.18	-139.3	-550.86	-97.83	-648.47	648.06	1,159.97	1,932.01	2,530.08	3,017.36	- -	3,534.91
Tangible Book Value per Share	6,143.97	5,784.23	7,724.58	5,365.56	6,503.85	5,854.81	5,391.61	5,613.12	6,155.22	6,723.49	7,252.56	7,751.29	- -	8,248.47
Basic Weighted Avg Shares	19	21	20	29	36	43	43	43	43	44	43	44	- -	43
Sales/Revenue/Turnover	46,968	52,657	66,744	74,732	104,811	135,860	146,880	173,513	233,568	398,738	386,040	388,794	477,835	477,835
Operating Margin (%)	10.81	14.23	12.51	-18.1	-14.32	6.38	2.43	8.49	10.12	11.99	9.89	9.28	7.79	7.79
Depreciation Expense	1,160	1,050	1,187	4,442	12,069	12,234	12,712	13,023	13,470	16,378	17,419	19,725	20,093	20,093
Net Income, GAAP	3,552	2,613	5,869	-15,207	-21,106	2,715	-9,389	8,602	20,940	34,579	25,960	21,265	21,966	21,966
Effective Tax Rate (%)	- -	27.86	0.68	- -	- -	- -	- -	2.74	- -	18.68	14.8	18.86	26.19	26.19
Profit Margin (%)	7.56	4.96	8.79	-20.35	-20.14	2	-6.39	4.96	8.97	8.67	6.72	5.47	4.6	4.6
Working Capital	34,237	114,273	34,864	36,860	99,455	86,816	54,926	39,717	46,027	71,226	99,920	115,485	144,023	144,023
LT Debt	64,065	165,570	84,401	114,089	89,000	48,125	34,375	38,811	57,851	39,398	21,823	5,862	15,089	15,089
Total Equity	157,246	168,412	214,426	192,314	276,706	293,624	270,035	280,031	300,561	331,969	356,787	376,666	396,922	396,922
Return on Invested Capital (%)	- -	1.82	2.27	- -	- -	- -	- -	3.35	- -	7.72	6.28	5.51	4.93	4.93
Return on Capital (%)	- -	2.29	4.34	- -	- -	- -	- -	8.87	- -	15.34	11.67	9.92	8.88	8.88
Return on Common Equity (%)	18.13	11.26	20.5	- -	- -	- -	- -	- -	53.97	51.79	26.75	17.62	15.43	15.43

	Jun'24	Sep'24	Dec'24
Total Current Assets	372,584	375,796	391,673
Accounts Receivable, Net	202,787	196,621	212,936
Cash, Cash Equivalents & STI	36,167	49,219	69,600
Inventories	124,494	124,239	101,392
Total Current Liabilities	248,274	237,318	247,650
Payables & Accruals	- -	- -	- -
ST Debt	165,476	161,330	157,082
Deferred Revenue	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	93.29	164.99	174.5	- -	596.83
2023	146.94	231.29	72.56	- -	488.57
2024	43.81	128.57	190.48	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	88,756	105,391	103,795	88,097	386,040
2023	90,010	110,245	93,385	95,154	388,794
2024	96,969	117,155	128,130	135,582	477,835

Celltrion Pharm, Inc.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Capital Structure

Working Capital

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year